Gsk (GLAXF) Cash from Financing Activities (2009 - 2026)

Gsk's Cash from Financing Activities history runs 18 years deep, the most recent figure standing at $366.7 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 66.07% year-over-year to $366.7 million; the TTM figure through Mar 2026 stood at -$3.1 billion (up 23.14% YoY), while the FY2025 annual figure was -$4.9 billion, up 19.57% from the prior year.
• Cash from Financing Activities was $366.7 million for Q1 2026 at Gsk, up from -$1.1 billion in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $10.7 billion in Q1 2022 to a low of -$3.4 billion in Q4 2024.
• Historically, Cash from Financing Activities has averaged $1.1 billion across 5 years, with a median of -$356.2 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities soared 663.85% in 2022, then sank 852.69% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $4.1 billion in 2022, then plunged by 108.71% to -$356.2 million in 2023, then sank by 852.69% to -$3.4 billion in 2024, then jumped by 66.45% to -$1.1 billion in 2025, then surged by 132.21% to $366.7 million in 2026.
• The last three Cash from Financing Activities figures came in at $366.7 million (Q1 2026), -$1.1 billion (Q4 2025), and $1.1 billion (Q1 2025), per Business Quant data.